Saturday 17 October 2026
Export GTBP’s income statement to Excel — free account
GT Biopharma, Inc.
GTBP Healthcare Biotechnology
In the quarter to June 2026, EPS grew 98.9% and free cash flow fell 41.3%, each against the same quarter a year earlier.
7.03
0.33
−4.48%
Follow GTBP
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
3.50 | 0.72 | 2.12 | 3.35 | 3.14 | 0.16 | 0.01 | 0.01 | 0.22 | 0.00 |
Net Debt/EBITDA |
0.56 | 0.28 | 1.03 | 0.78 | 0.56 | (3.26) | (0.85) | (0.04) | 0.00 | (1.73) |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 464.64% | 3,335.10% | 42.02% | 0.01% | 44,956.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.89) | (0.68) | 0.94 | 0.00 | (0.59) |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.37 | 0.98 | 1.17 | 0.73 | 0.27 | 0.26 | 0.09 | 0.04 | 0.04 | (0.20) |
Capex/Depreciation |
— | — | — | — | — | 0.00 | 0.39 | 0.00 | 0.00 | 0.00 |
Interest Coverage |
(97.81) | — | (63.74) | (2,657.12) | (80.10) | (2.25) | (7.55) | (27.43) | (15.76) | (1.43) |
| (1,674.31%) | (453.55%) | (79.10%) | (124.15%) | 1,541.48% | 116.09% | 972.88% | (197.06%) | (123.88%) | (28.11%) | |
| (558.42%) | (143.53%) | (49.26%) | (85.41%) | (306.70%) | (934.32%) | (299.65%) | (185.29%) | (113.35%) | 24,729.11% | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (710.97%) | (33.74%) | 0.00% |
Return on Tangible Assets |
(595.28%) | 788.14% | (102.34%) | (179.66%) | (264.78%) | 96.14% | 198.88% | 1,864.11% | 6,875.15% | (51.62%) |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.99 | 1.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(58.57) | (170.01) | (164.23) | (358.05) | (416.16) | (1,252.07) | (768.67) | (2,746.92) | (4,180.00) | 0.00 |
Cash per Share |
31.32 | 53.28 | 259.22 | 388.42 | 852.77 | 913.28 | 6.22 | 15.38 | 443.08 | 0.00 |
Shareholders Equity per Share |
26.24 | (22.00) | 138.70 | 276.09 | 584.27 | (5,074.66) | (4,291.11) | 2,915.38 | 193,606.92 | 0.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
26.24 | (22.00) | 138.70 | 276.09 | 584.27 | (5,074.66) | (4,291.11) | 2,915.38 | 193,606.92 | 0.00 |
Free Cash Flow |
(12.91) | (12.90) | (8.85) | (15.22) | (15.61) | (7.26) | (3.46) | (10.71) | (5.43) | (1.93) |
Working Capital |
5.79 | (1.67) | 7.42 | 11.62 | 21.91 | (29.43) | (19.43) | (13.94) | (2.10) | (18.93) |
Capital Expenditures |
— | — | — | — | — | — | 0.20 | (0.04) | 0.00 | — |
Net Current Asset Value |
5.79 | (1.67) | 7.42 | 11.56 | 21.91 | (29.43) | (19.43) | (13.94) | (2.10) | (18.93) |
| Other line items | ||||||||||
Quick Ratio |
2.98 | 0.69 | 2.11 | 3.34 | 3.12 | 0.15 | 0.00 | 0.00 | 0.22 | 0.00 |
Depreciation/Fixed assets |
— | — | — | 0.00 | — | 0.00 | 0.00 | 278.46 | 819.33 | 724.50 |
Cash ROIC |
(101.75%) | (543.56%) | (41.27%) | (53.88%) | (28.96%) | (335.12%) | 56.94% | (48.47%) | (2.15%) | 25.18% |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(58.57) | (170.01) | (164.23) | (358.05) | (416.16) | (1,252.07) | (813.11) | (2,737.69) | (4,176.92) | 0.00 |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 44.44 | (9.23) | (3.08) | 0.00 |
Average Payables |
2.30 | 4.09 | 3.73 | 5.66 | 5.22 | 2.09 | 1.85 | 2.15 | 2.32 | 1.50 |
Average Assets |
6.17 | 9.17 | 15.42 | 24.45 | 18.92 | 3.03 | 12.90 | 139.88 | 127.20 | 0.04 |
Average Common Equity |
2.06 | 2.90 | 9.60 | 16.82 | (3.76) | (24.37) | (3.97) | 131.53 | 116.38 | (34.75) |
Capex to Sales |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 | — |
Columns are period end dates